Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms

(2016) M. Araki et al.   BLOOD

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation

(2016) S. Elf et al.   Cancer Discovery

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants

(2015) I. Chachoua et al.   BLOOD

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis

(2015) C. Marty et al.   BLOOD

Ruxolitinib is an effective treatment forCALR-positive patients with myelofibrosis

(2015) Paola Guglielmelli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

(2015) Alessandro M. Vannucchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

(2014) R. Rampal et al.   BLOOD

Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator

(2014) T. Kameda et al.   BLOOD

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

(2014) John T. Reilly et al.   BRITISH JOURNAL OF HAEMATOLOGY

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

(2013) G. Rotunno et al.   BLOOD

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

(2013) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype

(2013) A Tefferi et al.   LEUKEMIA

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

(2011) A. Alvarez-Larran et al.   BLOOD

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

(2007) R. Tiedt et al.   BLOOD